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Background. Homocysteine (Hcy) appears to be involved in the development of intimal hyperplasia and arterial throm-
bosis. The purpose of this study was to evaluate the association of plasma Hcy with early re-stenosis following carotid ever-
sion endarterectomy.
Patients and methods. Of 398 consecutive patients, 363 were included in this study. 62% of patients had symptomatic
internal carotid artery (ICA) stenosis. Patients had preoperative assessment of Hcy and other well established atheroscle-
rosis risk factors. Intraoperatively, completion angiography was performed in 2 planes. Patients had clinical, Hcy and
duplex follow up at 1, 3, 18 and 36 months postoperatively.
Results. Complete follow up data were available for 312 patients. Five patients suffered from strokes and 2 patients died
during the peri-operative period (combined stroke and death rate of 2%). Mean follow up was 26 5 months (range 17 to
36 months). Seventeen and six patients (5.5%) developed a 50e69% and >70% re-stenosis, respectively. Serum creatinine
was significantly higher in patients with early re-stenosis, occlusion or stroke after CEA (P¼ 0.043). High grade
re-stenosis, occlusion and stroke ipsilateral to the operated side (17 patients) was associated with HbA1C and creatinine
(P¼ 0.043 and 0.046, respectively) but not Hcy.
Conclusion. While Hcy is a recognized independent risk factor for atherothrombosis, our study suggests that there is no
association of Hcy with early re-stenosis after eversion endarterectomy.
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Homocysteine (Hcy) is a sulfur-containing amino acid
formed during methionine metabolism.1 Elevated
plasmaHcy levels havebeen reported to be an indepen-
dent risk factor for coronary, cerebral, and peripheral
arterial occlusive disease.2e5 Moreover, Hcy appears
to be involved in the genesis of post-procedural intimal
hyperplasia and arterial thrombosis. In vitro Hcy has
been shown to be a potent mitogen, leading to marked
increase in vascular smooth-muscle cell proliferation6
and it has been proposed thatHcypromotes atherogen-
esis specifically by inducing the proliferation of vascu-
lar smooth-muscle cells.7
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(CEA) the degree of post-CEA intimal hyperplasia
was directly related to plasma levels of Hcy. Increas-
ing levels of plasma Hcy enhanced and accelerated
smooth muscle cell response after CEA leading to in-
creased intimal hyperplasia and luminal stenosis.8,9
Also of note, endarterectomy under general anesthe-
sia increases total Hcy in animals,10 an effect that
was not seen in humans using local anaesthesia.11
Literature regarding the influence of Hcy on the
development of early restenosis after carotid surgery
in man is sparse and conflicting. So far, three clinical
studies have been published, one retrospective,12 the
others prospective.13,14 It was concluded in one study
that restenosis is only associated with elevated Hcy
after CEA at levels of >30 mmol/l.12 A second study
suggested that elevated Hcy was protective against
restenosis after CEA.13 In the latest study an associa-
tion between elevated Hcy and re-stenosis after CEA
was demonstrated.14rved.
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evaluate the association of plasma Hcy with early
restenosis following carotid eversion endarterectomy
under local anaesthesia.
Patients and Methods
Patients
Of three hundred ninety eight consecutive patients
with symptomatic and asymptomatic internal carotid
artery (ICA) stenosis >70% admitted for surgery to
our department, 28 refused to participate in the study.
The remaining 370 were enrolled in the study during
a fifteen month period. All patients were planned for
routine eversion endarterectomy (EEA) of the ICA
under regional anaesthesia, and underwent pre-
operatively duplex scanning and magnetic resonance
angiography to assess the maximum lumen reduction
of the ICA. Symptomatic patients with non disabling
stroke had an interval of less than six weeks prior to
surgery; symptomatic patients with transient hemi-
spheric and non hemispheric symptoms were all
operated on within 3 weeks of presentation. Patients
were counselled and encouraged to reduce modifiable
cardiovascular risk-factors and to eat a healthy diet.
Preoperative measurement of fasting total plasma
Hcy, total cholesterol, LDL cholesterol, HDL choles-
terol, triglycerides, glycated haemoglobin (HbA1C),
serum creatinine as well as assessment of hyperten-
sion, smoking habits, body mass index (BMI) and
history of diabetes were done up to one week prior
to surgery. All patients had an intraoperative comple-
tion angiography in two planes after reconstruction of
the ICA. All patients gave written informed consent;
the study was approved by the local ethics committee
and in accordance to the declaration of Helsinki.
Sample handling and laboratory measurements
Blood was drawn by venipuncture of the antecubital
vein and collected in standard serum and K3-EDTA
tubes (Vacuette EDTATubes, Greiner Bio-One, Krems-
mu¨nster, Austria). Blood samples were centrifuged
(10 minutes at 2,000 G) and plasma for Hcy analysis
was decanted within 15 minutes after sampling and
stored at minus 80 degrees Celsius until analysis.
Hcy measurements were performed on an Abbott Ax-
SYM Plus Immunology analyzer (Abbott Diagnostics,
Abbott Park, IL, USA) using Abbott AxSYM Hcy re-
agents according to manufacturer’s instructions. The
sensitivity of the AxSYM homocysteine assay was as-
sessed to be 0.8 mmol/l by replicate analyses of thezero-level calibrator. Sensitivity was defined as the
concentration at two standard deviations from the
mean and represents the lowest measurable concen-
tration of Hcy that can be distinguished from zero.
The coefficient of variation (CV) resulting from
intra-assay precision experiments was between 4.5
and 1.4% at concentrations ranging from 7.6 to
28.2 mmol/l. Evaluating inter-assay imprecision in
the same concentration range the CV was between
2.0 and 5.1%.
Analysis of total cholesterol, HDL cholesterol,
triglycerides and creatinine in serum was performed
on a Hitachi 917 analyzer (Roche Diagnostics, Man-
nheim, Germany), HbA1C in K3-EDTA whole blood
was analyzed on a Cobas Integra 700 analyzer (Roche
Diagnostics, Basel, Switzerland) according to manu-
facturer’s instructions.
Follow up
Patients included in the study had clinical and mor-
phological (Duplex) follow up at 1, 3, 18 and 36
months post operation. A second measurement of
Hcy was performed between 18 and 36 months post-
operatively. Only patients with complete follow up
were evaluated. The progression of lumen stenosis
from the first to the second postoperative measure-
ment was assessed for all patients. Endpoints for cases
were defined as degrees of restenosis of 50%e69%
(low grade restenosis) and stenosis 70% to 99%
(high grade restenosis), recurrence of symptoms,
stroke and stroke related death ipsilateral to the oper-
ated ICA during follow up.
Duplex criteria
Duplex grading of ICA stenosis was according to pre-
viously published criteria.15,16 Peak systolic velocities
(PSV) within the ICA of 150 to 249 mm/sec and the
ratio of PSV of the ICA and common carotid artery
(CCA) of 2.0 to 3.9 were quantified as 50% to 69%
stenosis. PSV within the ICA greater 250 mm/sec
and the ratio of PSV of the ICA and CCA of greater
4 were quantified as 70% to 99% stenosis.
Statistical analysis
The study was designed as a case-control analysis
following a prospective data collection. After final
completion of data collection, patients were allotted
to the case group or control group based on the results
of duplex grading of ICA. A patient was regarded as
a case if during follow up a re-stenosis of 50%,Eur J Vasc Endovasc Surg Vol 33, February 2007
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the operated ICA occurred. All other patients were
regarded as controls.
Results were analyzed using a software package
(Epi-Info 2002 software package, Centers for Disease
Control and Prevention, Atlanta, GA, USA).
Continuous variables were shown as mean SD to-
gether with minimum and maximum values (range);
means were compared with a Student’s t-test for un-
paired variables. Discrete variables were expressed as
numbers (percentages) and compared by chi-square
test or by Fisher’s exact test, where appropriate.
Because our null hypothesis stated that Hcy levels
12 mmol/l are associated with early re-stenosis or oc-
clusion after CEA, one-sided P values were computed.
P values of  .05 were considered significant.
Results
Of 370 patients prospectively enrolled in the study, 1
had a PTFE interposition and 6 were operated under
general anaesthesia. Thus 363 were included in the
study. 198 were male, 165 female and their age ranged
from 40 to 92 years (mean 71 9). 139 patients (38%)
had asymptomatic ICA stenosis, 151 patients (42%)
had transient ischemic episodes and 73 patients
(20%) were operated on for non-disabling stroke.
Five patients suffered from perioperative stroke (one
associated with ICA occlusion), 2 patients died perio-
peratively (one stroke related death), accounting for
a perioperative stroke and death rate of 2%. Of the
Five patients with stroke 3 were lost to follow up.
Complete follow up data were available for 312 of
363 patients (86%) enrolled in the study (Tables 1
and 2).
Two hundred seventy eight patients had an
uneventful follow up without reaching any studyEur J Vasc Endovasc Surg Vol 33, February 2007endpoint. One hundred and sixty four patients
(59%) were male, 114 (41%) female, their mean age
was 71 8 years (range 40 to 92). Mean follow up
was 26 6 months (range 18 to 38 months).
Thirty four patients fulfilled criteria of the endpoint
(11%), 17 patients (5.5%) had a re-stenosis between 50
and 69%, 6 patients (2%) developed a re-stenosis of
>70%, 6 patients (2%) died of stroke ipsilateral to
the operated side and 5 patients (1.6%) had an asymp-
tomatic occlusion of the operated ICA. Twenty four
(70%) were male, 10 (30%) female, their mean age
was 71 8 years (range 56 to 84). Mean follow up
was 26 5 months (range 17 to 36 months).
Of all patients, 187 patients (60%) had Hcy levels
12 mmol/l, 165 patients with uneventful follow up
(60%) and 23 patients reaching the endpoint (67%;11
patients with low grade re-stenosis, 12 patients with
high grade re-stenosis, occlusion or stroke). There
was no statistically significant difference between
Hcy in these groups (no restenosis compared to all
cases P¼ 0.340; no restenosis compared to patients
with low grade restenosis P¼ 0.662; no restenosis
compared to patients with high grade restenosis, oc-
clusion or stroke P¼ 0.358; and low grade restenosis
compared to high grade restenosis, occlusion or stroke
P¼ 0.713).
Hcy in general and in both groups did not change
during follow up. Preoperative Hcy for all patients
compared to follow up was 14.20 7.05 mmol/l
(5.96e89.23 mmol/l) and 14.19 6.98 mmol/l (5.90e
81.11 mmol/l). Preoperative Hcy for cases was 15.03
5.08 mmol/l (8.23e30.23 mmol/l) prior to operation and
15.00 5.08 mmol/l (8.13e34.09 mmol/l) during follow-
up. Preoperative Hcy for all controls compared to
follow up was 14.09 7.26 mmol/l (5.96e89.23) and
14.12 7.20 mmol/l (5.73e86.00 mmol/l).
Serum creatinine was significantly higher in
patients in which stenosis >70% or occlusionTable 1. Continuos variables
Risk factor Cases n¼ 34 Controls n¼ 278 All n¼ 312 P-value
Mean SD (range) Mean SD (range) Mean SD (range)
Homocystein mmol/l 15.03 5.08 (8.23e30.23) 14.09 7.26 (5.96e89.23) 14.20 7.05 (5.96e89.23) 0.233
BMI kg/m2 25.97 4.37 (16.44e34.50) 26.14 3.66 (16.16e38.97) 26.12 3.74 (16.16e38.97) 0.399
HbA1C % 6.15 0.94 (4.80e9.00) 6.02 0.87 (4.80e10.40) 6.03 0.88 (4.80e10.40) 0.196
Creatinine mmol/l 105.2 27.4 (44.2e185.6) 96.4 27.4 (44.2e256.4) 97.2 30.1 (44.2e256.4) 0.043*
Cholesterol mmol/l 5.14 1.02 (3.78e8.35) 5.21 1.05 (2.59e10.32) 5.20 1.05 (2.59e10.32) 0.351
HDL mmol/l 1.35 0.38 (0.75e2.43) 1.37 0.41 (0.41e3.78) 1.37 0.41 (0.41e3.78) 0.389
LDL mmol/l 3.03 0.94 (1.78e6.36) 3.03 0.95 (0.96e7.76) 3.03 0.95 (0.96e7.76) 0.493
Triglicerides mmol/l 1.68 0.87 (0.58e5.31) 1.78 0.97 (0.43e7.81) 1.77 0.96 (0.43e7.81) 0.285
Uric acid mmol/l 379.0 102.3 (178.5e701.9) 356.9 97.6 (119.0e832.8) 359.3 98.2 (119.0e832.8) 0.114
Follow up (months) 26 5 (17e36) 26 6 (18e48) 26 6 (17e48) 0.327
Age (years) 71 8 (56e84) 71 9 (40e92) 71 9 (40e92) 0.478
BMI: body mass index; HDL high density lipoprotein; LDL: low density lipoprotein.
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Risk factor Cases n¼ 34 (%) Controls n¼ 278 (%) All n¼ 312 (%) OR 95% CI P-value
Male 24 (71) 164 (59) 188 (60) 1.67 0.73e3.90 0.192
Female 10 (29) 114 (41) 124 (40) 0.60 0.26e1.37 0.192
CAD; asymptomatic 16 (47) 117 (42) 133 (43) 1.22 0.57e2.64 0.579
CAD; TIA 12 (35) 104 (37) 116 (37) 0.91 0.41e2.03 0.809
CAD; stroke 6 (18) 57 (21) 63 (20) 0.83 0.27e2.18 0.695
Current smoker 9 (26) 79 (28) 88 (28) 0.91 0.37e2.15 0.811
Diabetic 12 (35) 73 (28) 85 (27) 1.53 0.67e3.44 0.263
Hypertension 29 (85) 227 (82) 256 (82) 1.30 0.45e404 0.601
CAD: carotid artery disease; TIA: transient ischaemic attack.developed during follow-up compared to controls
(two tailed t-test, p¼ 0.043). All other parameters,
including Hcy, did not differ statistically significantly.
Comparing only patients with high grade resteno-
sis, occlusion and stroke ipsilateral to the operated
side (17 patients), HbA1C and creatinine, but no
Hcy, were significantly elevated compared to patients
without restenosis (two tailed t-test, p¼ 0.043 and
0.046, respectively).
Discussion
Hcy has been described as an independent risk factor
for recurrent stroke and major vascular events.4,17e19
Reduction of Hcy levels by supplementation of folic
acid, pyridoxine and cobolamin, however, had no ef-
fect on recurrent stroke or myocardial infarction.17
Yet, reduction of Hcy after endovascular intervention
of coronary arteries significantly reduced the inci-
dence of major vascular events.2 This effect was
explained by a reduction of the prothrombotic
propensities of Hcy and its stimulating effects on pro-
liferation of vascular smooth muscle cells and thus
intima-media thickening.2
To date, the effect of Hcy on early restenosis after
CEA has not been answered unequivocally. Prospec-
tive studies have yielded contradictory results and in-
cluded very small sample sizes of 86 and 68 patients,
respectively.13,14 In our current study, 34 patients (11%
of all with complete follow up) reached a combined
endpoint of re-stenosis, occlusion, stroke and stroke
associated death ipsilateral to the operated ICA
during a mean follow up of 26 months. Six patients
(2%) had a high grade restenosis (>70%), one being
symptomatic. This finding is in keeping with large
randomized trials for restenosis after eversion endar-
terectomy of the ICA.20 As all patients had intraoper-
ative angiography and Duplex scanning one to three
months postoperatively, residual stenoses were
excluded as confounders.In total, 60% of our patient population had an Hcy
of 12 mmol/l, a threshold reported to bear a 2.2 fold
relative risk of vascular disease.21 There was no statis-
tically significant difference in Hcy levels between
cases and controls. Thus, it appears that atherothrom-
botic effects of Hcy alone do not play a prominent role
in early re-stenosis or occlusion after eversion endar-
terectomy of the ICA under local anesthesia.
There was also no association of other traditional
risk factors with restenosis. Cases had, however, a sig-
nificantly elevated serum creatinine compared to
patients without re-stenosis. These findings corrobo-
rate previous reports that re-stenosis after carotid
endarterectomy possibly differs from mechanisms of
atherosclerosis leading to lumen reduction5 or re-
stenosis after endovascular interventions with and
without stent.2
Importantly, when comparing only patients with
high grade re-stenosis (6 patients), asymptomatic oc-
clusion (5 patients) and stroke ipsilateral to the oper-
ated side (6 patients), HbA1C and creatinine, but not
Hcy, were significantly elevated compared to patients
without re-stenosis (two tailed t-test, p¼ 0.043 and
0.046, respectively). This is in keeping with observa-
tions indicating increased risk of cardiovascular and
cerebrovascular events in diabetic patients with
elevated Hcy.22e24
The molecular mechanisms of the detrimental
effects of Hcy in diabetics are not fully understood.
These effects may be due to an accelerated glucose
induced oxidative stress. Thus, the potentiation of
diabetic angiopathy by Hcy could be mediated by
impairment of NO formation and overproduction of
superoxide.25,26
Our study has one limitation. Based on previous
reports,17 our sample size calculation was performed
assuming a 20% difference in Hcy levels between
both groups of patients. To be able to detect a 20% dif-
ference at a power of 80% (two-tailed significance
0.05), we calculated that a total of 297 patients, 27 in
the case group, and 270 in the control group, would
be necessary. Therefore, our study is well powered toEur J Vasc Endovasc Surg Vol 33, February 2007
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deed, the difference between the Hcy means of our
cases and controls groups was only 7%. To be able to
detect a difference of 7% between two groups, we
would have had to encompass a total of 2387 patients,
217 in the cases group and 2170 in the controls group.
In conclusion, the results of this study do not dem-
onstrate a significant difference of plasma Hcy in pa-
tients with early re-stenosis, occlusion or stroke after
carotid endarterectomy compared to those without.
While Hcy is a recognized independent risk factor
for atherothrombosis, our study suggests that there
is no association of Hcy with early restenosis after
eversion endarterectomy.
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